We are live on ! Find out more
KRRO icon

Korro Bio

85 hedge funds and large institutions have $38.1M invested in Korro Bio in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 18 increasing their positions, 28 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

531% more call options, than puts

Call options by funds: $164K | Put options by funds: $26K

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

4% more funds holding

Funds holding: 8285 (+3)

0.12% less ownership

Funds ownership: 1.02%0.91% (-0.12%)

36% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 28

60% less capital invested

Capital invested by funds: $95M → $38.1M (-$57M)

Holders
85
Holders Change
+3
Holders Change %
+3.66%
% of All Funds
1.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
23
Increased
18
Reduced
28
Closed
20
Calls
$164K
Puts
$26K
Net Calls
+$138K
Net Calls Change
-$282K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$7M +$981K +5,136 +8%
Federated Hermes
2
Federated Hermes
Pennsylvania
$6.29M +$638K +3,340 +6%
N
3
Nuveen
North Carolina
$4.96M +$8.98K +47 +2%
WA
4
Wasatch Advisors
Utah
$4.89M -$3.29M -17,220 -27%
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.64M -$806K -4,219 -14%
JP Morgan Chase
6
JP Morgan Chase
New York
$2.23M -$444K -2,325 -10%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$1.25M +$58.1K +304 +3%
State Street
8
State Street
Massachusetts
$1.23M -$72.8K -381 -3%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$801K +$229K +1,199 +19%
GCP
10
GSA Capital Partners
United Kingdom
$639K +$312K +1,631 +37%
Renaissance Technologies
11
Renaissance Technologies
New York
$605K +$1.04M +5,443 +2,031%
Northern Trust
12
Northern Trust
Illinois
$579K -$52.9K -277 -5%
Amundi
13
Amundi
France
$420K -$32.1K -168 -3%
Goldman Sachs
14
Goldman Sachs
New York
$346K +$92.1K +482 +17%
Mariner
15
Mariner
Kansas
$273K +$491K +2,572 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$246K -$5.16K -27 -1%
Two Sigma Investments
17
Two Sigma Investments
New York
$234K +$21.6K +113 +5%
VOYA Investment Management
18
VOYA Investment Management
Georgia
$210K +$331K +1,731 +698%
SDIC
19
South Dakota Investment Council
South Dakota
$202K -$2.38M -12,434 -87%
BCM
20
Bridgeway Capital Management
Texas
$188K
Millennium Management
21
Millennium Management
New York
$183K +$114K +597 +53%
Walleye Capital
22
Walleye Capital
New York
$168K -$256K -1,341 -46%
Charles Schwab
23
Charles Schwab
California
$161K -$12.4K -65 -4%
PPA
24
Parametric Portfolio Associates
Washington
$154K -$42.4K -222 -13%
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$131K +$237K +1,240 New

KRRO Hedge Fund Activity: Q1 2022 in Review

85 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q1 2022, worth a combined $38.1M — down 60% from $95M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new KRRO positions and 20 closed out — a net gain of 3 holders — while 18 added to existing stakes and 28 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.04M. The largest seller was Lombard Odier Asset Management (Switzerland), exiting entirely with an estimated $3.63M sold.

  • 85 institutional investors held Korro Bio (KRRO) as of Q1 2022, up from 82 in Q4 2021.
  • Funds reported $38.1M of Korro Bio stock for Q1 2022, down 60% quarter-over-quarter.
  • 23 funds opened new Korro Bio positions in Q1 2022 and 20 closed out, a net change of +3 holders.
  • The largest Korro Bio buyer in Q1 2022 was Renaissance Technologies, an estimated $1.04M added.
  • The largest Korro Bio seller in Q1 2022 was Lombard Odier Asset Management (Switzerland), an estimated $3.63M sold.

Based on aggregated 13F filings for Q1 2022.